Evidence map›Paper›PMID 40365510›Full record

ReviewHealthcare technology letters

An Analysis of Monitoring Solutions for CAR T Cell Production.

Arber Shoshi, Yuchen Xia, Andrea Fieschi, Yannick Baumgarten, Andrea Gaißler, Thomas Ackermann, Peter Reimann, Bernhard Mitschang, Michael Weyrich, Thomas Bauernhansl and 1 more

Abstract readReview
In one paragraph

Review in Healthcare technology letters. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arber ShoshiGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.ORCID https://orcid.org/0000-0001-6029-4504
Yuchen XiaGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Andrea FieschiGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Yannick BaumgartenGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Andrea GaißlerFraunhofer Institute for Manufacturing Engineering and Automation (IPA) Stuttgart Germany.
Thomas AckermannGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Peter ReimannGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Bernhard MitschangGraduate School of Excellence advanced Manufacturing Engineering (GSaME) University of Stuttgart Stuttgart Germany.
Michael WeyrichInstitute of Industrial Automation and Software Engineering (IAS) University of Stuttgart Stuttgart Germany.
Thomas BauernhanslFraunhofer Institute for Manufacturing Engineering and Automation (IPA) Stuttgart Germany.
Robert MieheFraunhofer Institute for Manufacturing Engineering and Automation (IPA) Stuttgart Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The chimeric antigen receptor T cell (CAR T) therapy has shown remarkable results in treating certain cancers. It involves genetically modifying a patient's T cells to recognize and attack cancer cells. Despite its potential, CAR T cell therapy is complex and costly and requires the integration of multiple technologies and specialized equipment. Further research is needed to achieve the maximum potential of CAR T cell therapies and to develop effective and efficient methods for their production. This paper presents an overview of current measurement methods used in the key steps of the production of CAR T cells. The study aims to assess the state of the art in monitoring solutions and identify their potential for online monitoring. The results of this paper contribute to the understanding of measurement methods in CAR T cell manufacturing and identify areas where on-line monitoring can be improved. Thus, this research facilitates progress toward the development of effective monitoring of CAR T cell therapies.

Indexed as

advanced therapy medicinal product (ATMP)CAR T cell therapymonitoringon‐line measurement

Identifiers

PMID40365510
PMCPMC12073936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.